RDY — Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Q2 FY 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenue: INR 8,805 crores (USD 992 million), a growth of 9.8% year-over-year and 3% sequentially.
• EBITDA Margin: 26.7%, down 174 basis points year-over-year; adjusted for one-time provisions, the underlying margin was 27.5%.
• Profit Before Tax (PBT): INR 1,835 crores (USD 207 million), with an adjusted PBT margin of 21.6%.
• Profit After Tax: INR 1,437 crores (USD 162 million), a 14% year-over-year increase, flat sequentially.
• Diluted EPS: INR 17.25.
• Operating Working Capital: INR 13,331 crores (USD 1.5 billion).
• Free Cash Flow: INR 1,046 crores (USD 118 million).
• Net Cash Surplus: INR 2,751 crores (USD 310 million).

2. Strategic Updates and Business Highlights

• Consumer Health Care Integration: The acquisition of a consumer health care business contributed positively to revenue growth.
• Product Launches: Launched 7 new products in the U.S. and 8 in Europe, with a focus on expanding the portfolio in emerging markets.
• Pipeline Progress: Advancements in key pipeline products like semaglutide and abatacept; the latter is expected to have a BLA submission by December 2025.
• Regulatory Developments: Positive opinions received for biosimilar candidates in Europe; ongoing efforts to address FDA observations at various facilities.
• Sustainability Initiatives: Retained MSCI ESG Rating of A and improved ESG Risk Rating from Morningstar Sustainalytics.

3. Forward Guidance and Outlook

• U.S. Business: Anticipated continued revenue from Lenalidomide in Q3, albeit at reduced levels. The company expects to stabilize pricing dynamics in the U.S. generics market.
• EBITDA Margin Target: Management maintains a target of returning to 25% EBITDA margin in FY '27, driven by growth in key products and cost containment measures.
• Emerging Markets Growth: Confidence in maintaining double-digit growth in emerging markets, supported by new product launches and favorable foreign exchange rates.

4. Challenges and Points of Concern

• U.S. Generics Performance: The North American generics business saw a 16% year-over-year revenue decline, primarily due to price erosion and reduced contributions from Lenalidomide.
• Regulatory Risks: Ongoing challenges with FDA inspections and CRLs, particularly concerning the rituximab biosimilar, which may impact timelines for product launches.
• Margin Pressures: Declining gross profit margins due to lower sales of high-margin products and increased operational costs.
• Competitive Landscape: Increasing competition in the semaglutide market, with multiple players expected to enter, raising concerns about pricing pressures.

5. Notable Q&A Insights

• U.S. Business Outlook: Management indicated that while Lenalidomide sales will decrease, some revenue will still be generated in Q3. They are focusing on a robust pipeline to drive future growth.
• R&D Focus: The company is rationalizing its pipeline, concentrating on products with strong commercial potential, particularly in biosimilars and complex generics.
• Market Dynamics: Management acknowledged the competitive nature of the Canadian market for semaglutide, anticipating aggressive pricing strategies from multiple entrants.
• Cost Management: The company is committed to maintaining operational efficiency and has implemented measures to reduce SG&A expenses, aiming for a target of 28% to 30% of revenues.

Overall, Dr. Reddy's Laboratories reported steady financial performance in Q2 FY 2026, supported by strategic acquisitions and product launches, while navigating challenges in the U.S. generics market and regulatory landscape. The outlook remains cautiously optimistic, with a focus on sustaining growth and improving margins.